A chromatogram is a story about molecular identity. Those peaks and valleys emerging from high-performance liquid chromatography analysis reveal not just what's present in a peptide sample, but what went wrong during synthesis, what degraded during storage, and whether the compound you're working with matches what you ordered.
HPLC (High-Performance Liquid Chromatography) separates peptides based on their chemical properties as they pass through a packed column under high pressure. For peptide analysis, reversed-phase HPLC using C18 columns (silica particles bonded with 18-carbon hydrocarbon chains) provides the standard approach. The column's hydrophobic surface interacts with peptide molecules dissolved in a mobile phase, typically a gradient of water and acetonitrile.
The separation depends on each peptide's hydrophobicity. More hydrophobic sequences stick to the C18 surface longer, eluting later in the run. Less hydrophobic molecules pass through faster. A detector, usually measuring UV absorption at 220 nanometers where peptide bonds absorb strongly, tracks what emerges and when.
Reading the field
A chromatogram plots detector signal (usually in milliabsorbance units, mAU) against time. Each peak represents a compound or class of compounds with similar retention characteristics. The area under each peak correlates with the quantity of that substance.
In an ideal peptide synthesis, you'd see one dominant peak corresponding to your target sequence and minimal background noise. Reality delivers something messier. Most chromatograms show the main product peak plus several smaller peaks representing synthesis byproducts, truncations, and degradation products.
Purity percentage comes from dividing the area under the target peak by the total area of all peaks, then multiplying by 100. A peptide sold as "95% pure" means its target peak represents 95% of the total detected material. The remaining 5% consists of impurities identifiable as separate peaks.
This calculation assumes all compounds absorb UV light equally at 220 nm, which isn't precisely true but provides a reasonable approximation for peptides with similar structures.
The peak's shape matters as much as its area. A sharp, symmetrical peak indicates a well-defined compound eluting cleanly. Peak tailing, where the peak drags asymmetrically, suggests interaction with the column packing or sample degradation. Broad peaks might indicate multiple similar compounds eluting together, which could mask impurities.
Retention time, the point where the peak reaches maximum height, serves as a preliminary identity check. Each peptide sequence has a characteristic retention time under specific HPLC conditions. Significant deviation from expected retention suggests you're not analyzing the compound you think you are.
What Hides in the Baseline
Small peaks matter. That minor signal at 0.5% might represent a deletion sequence missing a critical amino acid residue, changing the peptide's biological activity entirely. Or it could be a harmless salt. The chromatogram doesn't distinguish.
Truncations are incomplete peptide chains where synthesis terminated early. If you're making a 20-amino-acid peptide and synthesis fails at position 15, you get a 14-amino-acid byproduct. These shorter sequences often appear as peaks eluting earlier than the target, being less hydrophobic due to fewer residues.
Deletion sequences missing one or more internal amino acids produce peaks with retention times close to the full-length product, making them harder to separate. A peptide missing a single hydrophobic residue might elute just slightly earlier, creating a shoulder on the main peak rather than a distinct signal.
Oxidation affects amino acids like methionine, cysteine, and tryptophan. Oxidized peptides typically elute slightly earlier than their reduced counterparts, appearing as minor peaks near the main product. Oxidation often occurs during storage rather than synthesis, making it a useful indicator of handling conditions.
Acetylated or amidated variants result from incomplete deprotection or intentional modifications. These can shift retention times in either direction depending on how they affect overall hydrophobicity.
The peptide synthesis process involves stepwise addition of protected amino acids to a growing chain. Each coupling step has an efficiency, typically 98-99.5%. Over 20 coupling cycles, that efficiency compounds. A 99% coupling efficiency across 20 steps yields approximately 82% full-length product. The remaining 18% consists of all possible deletion and truncation variants.
High-purity peptides require either exceptionally efficient synthesis or effective purification to remove these byproducts.
Thresholds and Compromises
Research-grade peptides typically fall into purity ranges: crude (50-70%), standard (75-85%), high purity (85-95%), and ultra-pure (>95%). The appropriate threshold depends on the application.
For cell culture screening where you're testing biological activity and can account for peptide content in dosing calculations, 85% purity often suffices. The impurities at 15% are mostly related sequences unlikely to produce off-target effects.
Structural studies using NMR or crystallography demand >95% purity. Minor contaminants create overlapping signals that complicate spectral interpretation.
Animal studies occupy a middle ground. If you're administering a peptide systemically, impurities might trigger immune responses or compete for receptors. Higher purity reduces confounding variables, but the cost escalates significantly above 90%.
The relationship between purity and price is non-linear. Achieving 95% purity from 85% starting material requires additional purification steps, each with yield losses. A 95% pure peptide might cost three times more than an 85% pure version of the same sequence, despite containing only 12% more actual product.
Researchers face an economic decision: pay for higher purity or account for impurities in experimental design and interpretation.
What HPLC Doesn't Tell You
UV absorption at 220 nm detects peptide bonds. It doesn't confirm sequence identity. A chromatogram showing 95% purity tells you that 95% of the detected material has a specific retention time. It doesn't prove that material is the peptide you ordered.
A synthesis error that swaps one amino acid for another of similar hydrophobicity might produce a peptide with nearly identical retention characteristics. The chromatogram looks perfect. The sequence is wrong.
Mass spectrometry (MS) provides molecular weight determination. Coupling HPLC with mass spectrometry (LC-MS) gives both separation and weight confirmation. The combination is powerful: HPLC separates components, MS identifies what each peak represents by measuring mass-to-charge ratios.
A peptide's expected molecular weight, calculated from its amino acid sequence, should match the mass spectrum's major ion within a few Daltons. Deviations indicate sequence errors, unexpected modifications, or degradation.
Amino acid analysis (AAA) hydrolyzes the peptide into constituent amino acids, then quantifies each. This confirms not just that you have the right molecular weight, but that the amino acid composition matches expectations. AAA catches substitution errors that MS might miss if the substituted amino acid has similar mass.
NMR spectroscopy can determine complete three-dimensional structure for pure peptides, but requires milligram quantities and specialized expertise.
Peptide characterization ideally uses orthogonal methods. HPLC for purity, MS for molecular weight, AAA for composition. Each technique reveals different aspects of molecular identity. Relying on HPLC alone provides incomplete assurance.
The Degradation Timeline
Peptides aren't stable indefinitely. Oxidation, deamidation, hydrolysis, and aggregation occur over time, even in lyophilized powder stored frozen.
Asparagine and glutamine residues undergo deamidation, converting to aspartic acid and glutamic acid. This adds one mass unit and changes the peptide's charge state, shifting HPLC retention time and potentially altering biological activity. Deamidation accelerates in solution and at elevated temperatures.
Disulfide bonds between cysteine residues can scramble, forming incorrect linkages. Peptides with multiple cysteines might show several peaks on HPLC representing different disulfide isomers.
Aggregation occurs when peptides associate non-covalently or form covalent cross-links. Aggregates often precipitate out of solution, reducing the concentration of active peptide without necessarily showing up as impurity peaks on HPLC.
Regular re-testing of peptide stocks catches degradation before it compromises research. A sample that tested at 95% purity two years ago might be 85% pure now. The difference appears as new peaks on the chromatogram, showing degradation products accumulating.
Storage conditions matter profoundly. Lyophilized peptides stored at -20°C or -80°C in desiccating conditions degrade slower than those stored at 4°C or room temperature. Dissolved peptides degrade faster than dry powder, with degradation rate depending on pH, buffer composition, and the specific amino acid sequence.
When Marketing Outpaces Methodology
The commercial peptide market includes suppliers ranging from specialized synthesis labs with rigorous quality control to bulk manufacturers providing crude material. Not all HPLC data carries equal weight.
A chromatogram image without supporting details means little. The critical information includes:
- Column type and dimensions
- Mobile phase composition and gradient program
- Flow rate and column temperature
- Detection wavelength
- Sample concentration and injection volume
- System calibration and baseline stability
Without these parameters, the chromatogram can't be evaluated properly or reproduced. Some suppliers provide partial chromatograms cropped to show only the main peak, hiding impurities that elute earlier or later.
Certificate of Analysis (COA) documents should include the complete chromatogram, purity calculation, molecular weight confirmation by MS, and batch-specific identification. Generic COAs using the same data for multiple batches indicate inadequate testing.
Third-party testing provides independent verification. Sending a sample to an analytical lab for HPLC and MS analysis costs $200-500 but confirms what you're working with, especially for critical experiments or when supplier reputation is uncertain.
The economics of peptide research create pressure to cut costs. Purchasing from the cheapest supplier might save 40% on peptide cost while introducing uncontrolled variables that invalidate months of experimental work. The calculus favors verification over trust.
Building a Reference Library
Researchers working regularly with specific peptides benefit from generating their own HPLC data. Running a reference standard on your institutional HPLC system establishes baseline retention time and peak profile under your specific conditions.
When a new batch arrives, a comparison run confirms consistency. Unexpected retention time shifts or additional peaks signal problems before you invest time in failed experiments.
For labs without HPLC access, collaborating with chemistry departments or using core facilities provides testing capabilities. Many institutions offer analytical services for internal users at subsidized rates.
The investment in characterization scales with research stakes. A preliminary screening experiment might tolerate standard-purity peptides with supplier-provided data. A study headed toward publication requires verification. Clinical translation demands forensic-level documentation.
Testing matters more than marketing because experimental reproducibility depends on molecular consistency. A well-characterized peptide from a mid-tier supplier outperforms a poorly documented product from a premium brand.
The chromatogram tells you what you have. Everything else is assumption.